Luminex
Luminex Obtains CE Marking for MDx Panel to Detect Flu A/B, RSV, COVID-19
Results are generated in a single workflow from a patient sample, which enables rapid detection for the differential diagnosis of a single pathogen.
Bio-Techne, Nonagen Bioscience Ink Agreement to Manufacture Multiplex Bladder Cancer Panel
Bio-Techne will manufacture Nonagen's Oncuria, a protein-based urine test for the early detection, therapy choice, and disease monitoring of bladder cancer.
DiaSorin Expects 2022 Revenue Growth From Base Business, Luminex as COVID-19 Testing Declines
Premium
DiaSorin CEO Carlo Rosa said that demand for the firm's SARS-CoV-2 tests peaked during the Omicron wave in December and January but declined sharply in recent weeks.
DiaSorin 2021 Revenues Rise 41 Percent on SARS-CoV-2, Luminex Sales Growth
Luminex contributed €195.0 million to DiaSorin's revenues in 2021 and saw strong performance from its Aries and Verigene molecular diagnostic platforms.
Luminex Gets CE Mark for Gastrointestinal Pathogen Panel
The molecular multiplex panel is designed to detect 16 pathogens associated with gastrointestinal infections in stool samples.